Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Dermatologic 1

Conditions

Keratosis, Actinic 2Skin Neoplasms 1Precancerous Conditions 1Carcinoma, Basal Cell 1

Interventions

Peripheral Blood Stem Cell Transplantation 9Cyclophosphamide 9Biopsy 8fludarabine phosphate 7Whole-Body Irradiation 6Tacrolimus 5Mycophenolic Acid 5Epoetin Alfa 5Colposcopy 5Celecoxib 5Busulfan 5Aminolevulinic Acid 5Sulindac 4Selenium 4Methotrexate 4Melphalan 4Cyclosporine 4Cetuximab 4Antilymphocyte Serum 4Polymerase Chain Reaction 3Imiquimod 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Gene Expression Profiling 3Etoposide 3Eflornithine 3Darbepoetin alfa 3Carboplatin 3Aspirin 3fludarabine 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Precancerous Conditions × Deoxyribonuclease (Pyrimidine Dimer) × Clear all
NCT00002811 2013-11-06

T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum

National Cancer Institute (NCI)

Phase 3 Unknown
30 enrolled
DermatologicOther neoplasm

Precancerous Conditions, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡